Related Experiment Video
Updated: Jun 24, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Abstract:
Drospirenone is a synthetic progestogen contained, with estradiol, in the hormone replacement therapy (HRT) product black triangle downAngeliq (Bayer Schering Pharma). This combination is licensed for the relief of oestrogen-deficiency symptoms in women who are at least 1 year postmenopausal.1 It is also licensed for prevention of osteoporosis in women at high risk of future fractures who are intolerant of, or have contraindications to, other medicinal products approved for the prevention of osteoporosis.1 It has also been suggested that drospirenone may have an antihypertensive effect.2 Here we discuss the place of this drug for women following a natural menopause.
Related Concept Videos
Intrauterine Drug Delivery Systems
Birth Control Methods
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Menopause
Transdermal Drug Delivery Systems
